Propanc Biopharma, Inc.: Form 10-Q for the period ended Sep 30, 2016
Filed with the SEC on Nov 10, 2016 and accepted by EDGAR at Nov 10, 2016, 17:29 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2016-07-01 to 2016-09-30 | $161.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-07-01 to 2016-09-30 | −$1.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-07-01 to 2016-09-30 | $471.4k | us-gaap:InterestExpense |
| Income tax | 3 months2016-07-01 to 2016-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-07-01 to 2016-09-30 | −$1.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-07-01 to 2016-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2016-07-01 to 2016-09-30 | −$683.6k | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months2016-07-01 to 2016-09-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-09-30 | $24.9k | us-gaap:Cash |
| Current assets | At period end2016-09-30 | $166.7k | us-gaap:AssetsCurrent |
| Total assets | At period end2016-09-30 | $181.4k | us-gaap:Assets |
| Current liabilities | At period end2016-09-30 | $2.0m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2016-09-30 | −$1.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-16-133411. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.